Mascha Binder
Prof. Dr. med.
Mascha Binder
  • Senior physician
  • Deputy director of the department
  • Medical Specialist in Internal Medicine
  • Facharzt für Hämatologie - Internistische Onkologie
Working area

Location

O43 , 1st Floor, Room number 104
Languages
German (Mother tongue)
Italian
English
French

Areas of expertise

Awards

Memberships

Publications

Zurück
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
Vor

A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells
Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, Binder M
LEUKEMIA LYMPHOMA. 2019;60(2):334-340.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib
Janjetovic S, Asemissen A, Dicker F, Binder M, Dierlamm J, Bokemeyer C, Schafhausen P
TUMORI . 2019 [Epub ahead of print];300891619839473.

Monoklonale Gammopathie unklarer Signifikanz – ein häufiger Nebenbefund
Schieferdecker A, Binder M, Weisel K, Bokemeyer C
DEUT MED WOCHENSCHR. 2019;144(14):982-989.

T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model
Schliffke S, Carambia A, Akyüz N, Thiele B, Herkel J, Binder M
J NEUROIMMUNOL. 2019;332:49-56.

Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
Bera T, Abe Y, Ise T, Oberle A, Gallardo D, Liu X, Nagata S, Binder M, Pastan I
LEUKEMIA. 2018;32(2):569-572.

Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Mohme M, Schliffke S, Maire C, Rünger A, Glau L, Mende K, Matschke J, Gehbauer C, Akyüz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt N, Peine S, Westphal M, Binder M, Tolosa E, Lamszus K
CLIN CANCER RES. 2018;24(17):4187-4200.

The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia
Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Riecken K, Fehse B, Nollau P, Binder M
BLOOD. 2018;131(15):1755-1758.

Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
Schliffke S, Sivina M, Kim E, Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger J, Binder M
ONCOIMMUNOLOGY. 2018;7(4):e1417720.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M
INT J CANCER. 2017;140(11):2535-2544.

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking
Braig F, Brandt A, Goebeler M, Tony H, Kurze A, Nollau P, Bumm T, Böttcher S, Bargou R, Binder M
BLOOD. 2017;129(1):100-104.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
Ferreri A, Cwynarski K, Pulczynski E, Fox C, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton K, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause S, Schmoll H, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi L, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G
LANCET HAEMATOL. 2017;4(11):e510-e523.

The role of B cell antigen receptors in mantle cell lymphoma
Fichtner M, Dreyling M, Binder M, Trepel M
J HEMATOL ONCOL. 2017;10(1):164.

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)
Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Möhle R, Löw S, Binder M, Atta J, Keller U, Wolf H, Krause S, Heß G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Röth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G
LEUKEMIA. 2017;31(4):846-852.

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo
Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, Binder M, Fliegert R, Guse A, Zhao Y, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F
SCI REP-UK. 2017;7(1):14289.

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma:a prospective multicentre trial by the German Cooperative PCNSL study group
Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, von Baumgarten L, Röth A, Bloehdorn J, Möhle R, Binder M, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G
LEUKEMIA. 2017;31(12):2623-2629.

Optimization of design and production strategies for novel adeno-associated viral display peptide libraries
Körbelin J, Hunger A, Alawi M, Sieber T, Binder M, Trepel M
GENE THER. 2017;24(8):470-481.

Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, Binder M
HAEMATOLOGICA. 2017;102(9):e368-e370.

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
Oberle A, Brandt A, Voigtländer M, Thiele B, Radloff J, Schulenkorf A, Alawi M, Akyüz N, März M, Ford C, Krohn-Grimberghe A, Binder M
HAEMATOLOGICA. 2017;102(6):1105-1111.

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
Rossi A, Voigtländer M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder M
BLOOD CANCER J. 2017;7(2):e537.

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
Alsdorf W, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M
J Oncol Pharm Pract. 2016;22(3):523-7.

Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT
Bacher U, Binder M
J TRANSL MED. 2016;4(Suppl 1):S19.

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Braig F, Voigtländer M, Schieferdecker A, Busch C, Laban S, Grob T, Kriegs M, Knecht R, Bokemeyer C, Binder M
ONCOTARGET. 2016;7(28):42988-42995.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Ferreri A, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi L, Torri V, Fox C, Rosée P, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton K, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv J, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause S, Levis A, Schmoll H, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G
LANCET HAEMATOL. 2016;3(5):e217-27.

Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma
Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Dierlamm J, Gerull H, Nollau P, Klapper W, Dreyling M, Binder M, Trepel M
HAEMATOLOGICA. 2016;101(9):e378-81.

High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
Illerhaus G, Kasenda B, Ihorst G, Egerer G, Lamprecht M, Keller U, Wolf H, Hirt C, Stilgenbauer S, Binder M, Hau P, Edinger M, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, von Baumgarten L, Deckert M, Hader C, Fricker H, Valk E, Schorb E, Fritsch K, Finke J
LANCET HAEMATOL. 2016;3(8):e388-97.

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, Binder M, Rieckmann T, Grénman R, Petersen C, Dikomey E, Rothkamm K
ONCOTARGET. 2016;7(29):45122-45133.

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Miethe S, Hust M, Braig F, Voigt M, Pein U, Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, Binder M
BLOOD. 2016;127(25):3202-14.

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia
Schliffke S, Akyüz N, Ford C, Mährle T, Thenhausen T, Krohn-Grimberghe A, Knop S, Bokemeyer C, Binder M
LEUKEMIA. 2016;30(11):2232-2234.

Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib
Shumilov E, Wulf G, Ströbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Braulke F, Jung W, Schanz J, Binder M, Trümper L, Bacher U
LEUKEMIA LYMPHOMA. 2016;1-5.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies: author's reply
Flammiger A, Binder M
LEUKEMIA LYMPHOMA. 2015;56(12):3455.

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia
Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink A, Eichhorst B, Kreuzer K, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner C, Bergmann M, Fischer K
EUR J HAEMATOL. 2015.

Comment on "Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins"
Spies E, Fichtner M, Müller F, Krasemann S, Illerhaus G, Glatzel M, Binder M, Trepel M
J IMMUNOL. 2015;195(10):4549-50.

Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type
Voigtländer M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, Binder M
ANN HEMATOL. 2015;94(9):1559-65.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
Yousef S, Kovacsovics-Bankowski M, Salama M, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D
HUM VACC IMMUNOTHER . 2015;11(7):1606-11.

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Kröger N, Luetkens T, Atanackovic D
BLOOD CANCER J. 2015;5:e285.

The role of CD81 for plasma cell dyscrasias
Binder M, Bacher U
LEUKEMIA RES. 2014;38(3):292-3.

Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance
Flammiger A, Bacher U, Christopeit M, Horn C, Rühlmann E, Kluge K, Vettorazzi E, Bokemeyer C, Binder M
LEUKEMIA LYMPHOMA. 2014;56(3):639-644.

Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia
Rissiek A, Schulze C, Bacher U, Schieferdecker A, Thiele B, Jacholkowski A, Flammiger A, Horn C, Haag F, Tiegs G, Zirlik K, Trepel M, Tolosa E, Binder M
INT J CANCER. 2014;135(10):2370-2379.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma
Thiele B, Kloster M, Alawi M, Indenbirken D, Trepel M, Grundhoff A, Binder M
BLOOD. 2014;123(23):3618-21.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL.
Binder M, Müller F, Frick M, Wehr C, Simon F, Leistler B, Veelken H, Mertelsmann R, Trepel M
BLOOD. 2013;121(1):239-241.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies.
Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller L, Christopeit M, Bacher U
ACTA HAEMATOL-BASEL. 2013;129(3):135-136.

Identification of genetic parameters associated with disease progression in plasma cell myeloma.
Bacher U, Binder M
LEUKEMIA RES. 2012;36(1):23-24.

Acceleration of collateral development by carcinoembryonic antigen-related cell adhesion molecule 1 expression on CD11b/⁺Gr-1⁺ myeloid cells--brief report
Bickert T, Marshall R, Zhang Z, Ludewig P, Binder M, Klinke A, Rottbauer W, Amling M, Wagener C, Ito W, Horst A
ARTERIOSCL THROM VAS. 2012;32(11):2566-8.

Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis
Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass J, Walker U, Peter H, Warnatz K
ANN RHEUM DIS. 2012;71(2):311-2.

Evaluation of BM cytomorphology after allo-SCT in patients with AML.
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-44.

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.
Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M
ACTA HAEMATOL-BASEL. 2012;128(2):69-72.

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation
Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M
CANCER IMMUNOL IMMUN. 2012;61(10):1639-51.

Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation.
Rahlff J, Trusch M, Haag F, Bacher U, Horst A, Schlüter H, Binder M
CANCER IMMUNOL IMMUN. 2012;61(10):1639-1651.

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.
Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, Binder M
PLOS ONE. 2012;7(2):31998.

Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M, Braig F, Goethel M, Schulte A, Lamszus K, Bokemeyer C, Binder M
NEOPLASIA. 2012;14(11):1023-1031.

Anti-tumor activity of a B-cell receptor-targeted peptide in a novel disseminated lymphoma xenograft model.
Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, Binder M, Fiebig H, Mertelsmann R, Trepel M
INT J CANCER. 2012;131(2):10-20.

B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia.
Binder M, Müller F, Jackst A, Lechenne B, Pantic M, Bacher U, Zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M
CANCER-AM CANCER SOC. 2011;117(9):1891-1900.

Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells
Binder M, Léchenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, Schlüter H, Braren I, Spillner E, Trepel M
PLOS ONE. 2010;5(12):e15992.

Drugs targeting integrins for cancer therapy
Binder M, Trepel M
EXPERT OPIN DRUG DIS. 2009;4(3):229-41.

Isopathic treatment effects of Arsenicum album 45x on wheat seedling growth--further reproduction trials.
Lahnstein L, Binder M, Thurneysen A, Frei-Erb M, Betti L, Peruzzi M, Heusser P, Baumgartner S
Homeopathy. 2009;98(4):198-207.

XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors.
Hackanson B, Becker H, Berg T, Binder M, Dierks C, Duque-Afonso J, Lairmore M, Schäfer H, Schnitzler M, Zeiser R, Martens U, Mertelsmann R, Lübbert M
CANCER RES. 2008;68(14):5512-5518.

Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab
Binder M, Vögtle F, Michelfelder S, Müller F, Illerhaus G, Sundararajan S, Mertelsmann R, Trepel M
CANCER RES. 2007;67(8):3518-23.

The epitope recognized by rituximab
Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M
BLOOD. 2006;108(6):1975-8.

The effects of a 45x potency of arsenicum album on wheat seedling growth -- a reproduction trial.
Binder M, Baumgartner S, Thurneysen A
FORSCH KOMP KLAS NAT. 2005;12(5):284-291.

Letzte Aktualisierung aus dem FIS: 18.08.2019 - 05:19 Uhr